DALLAS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced the pricing terms for its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes). All other terms and conditions of the Tender Offer remain unchanged and are described in the Offer to Purchase, dated August 11, 2025 (the “Offer to Purchase”). Capitalized terms used in this news release and not defined herein have the meanings given to them in the Offer to Purchase.
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Via Transportation, Inc. ("Via"), a leading provider of technology to power public transit networks, today announced that...
Long-time business partners Jim Chiate and Tony Guinane launch Dial Square Private Wealth to offer sophisticated clients enhanced services, greater support and broader investment...
SalMar ASA (“SalMar”), rated BBB+/Negative by Nordic Credit Rating, has issued NOK 1,000 million in a 8-year fixed tranche and 500 million in a 7-year floating rate tranche. The new senior unsecured green bonds are priced with fixed and floating rate coupons at 5.15% (equivalent to a floating rate of 3mN+143bps) and 3mN+135bps per annum, respectively.
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Gimme Credit's latest research shows that leading U.S. corporate issuers are holding firm against escalating tariffs and increasingly...
ESCO performance contracts gain traction as governments and businesses seek long-term energy savings and resilience
BOULDER, Colo., Aug. 14, 2025 /PRNewswire/ -- A new report from Guidehouse...
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.